Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Consumer-Directed Health Plans: Pharmacy Benefits & "Better Practices"

On behalf of the National Pharmaceutical Council, The Benfield Group conducted a multi-phase research project investigating pharmacy benefit designs attached to consumer-directed health plans (CDHPs). The research was intended to identify the current landscape and best practice approaches for CDHPs and pharmacy benefits, as well as understand the health and economic impact of best practice models and evidence about higher value approaches to CDHP pharmacy benefit design.

About CDHPs

CDHPs are high-deductible plans offered in combination with an account that enrollees can access to offset the deductible expense. Premiums are generally lower than in traditional plans because enrollees must meet the higher deductibles before traditional medical and pharmacy coverage begins. There are two main types of CDHPs:

  • Health savings accounts (HSAs) are the predominant type of CDHP. Some employers and benefits advisors consider HSAs to be more advantageous to employees, who can deposit part of their pre-tax income and have ownership of the account, which they can use for medical, long term care and/or retirement expenses.
  • Health reimbursement accounts (HRAs), in which employees are reimbursed for medical services not covered under a health plan, are preferred by employers that like the HRAs’ flexibility and ability to recoup money when employees leave the company.

Findings

This research revealed that a standard CDHP model has emerged that employee benefits consultants (EBCs) routinely recommend and employers typically follow. Although employers’ strategies range in sophistication, most strategies include at least the following elements:

  • Communicate in advance of roll-out to prepare employees and educate them about what to expect and how CDHPs are different than what they’re used to;
  • Make a contribution to employees’ HSA or HRA accounts;
  • Cover preventive care (at least their interpretation of what is required by law);
  • Promote wellness and provide educational tools to help employees navigate health care choices; and
  • Monitor outcomes and make adjustments.

Though employers generally follow this standard model, diversity exists in CDHPs. Plans vary according to deductible levels, account contributions, coverage of prescription drugs, the level of wellness, decision support and financial literacy programs offered, and the integration of program offerings with plan design (eg, incentives).

For employees who are low income or who have high health care needs, however, these types of plans can impose a bigger burden of out-of-pocket costs, potentially causing these employees to reduce their compliance with necessary treatments or avoid care altogether.

CDHP “Better Practices”

Some employers are establishing “better practices” in overall CDHP plan design and in their approach prescription benefits. Some of the innovations are designed to have broad impact, providing support and aligning incentives across the workforce to improve health and health care decision-making. Other innovations are targeted at mitigating the harmful impacts of blunt CDHP and prescription benefit plan design on high health care need/low-income employees.

Key differentiating “better practices” include:

  • Use of integrated health and productivity data in plan design and performance measurement;
  • Lower net deductibles (deductible minus company HSA or HRA account contributions);
  • Varying contributions based on income (to protect low-income workers) or linking to incentives for wellness or consumer behaviors;
  • Implementation of value-based approach to prescription drug coverage in HRA-based plans; and
  • Implementation of broad list of preventive drugs, combined with a value-based approach in HSAs.

Methodology

As part of this project, Benfield conducted a survey of 96 large employers (1,000 to 4,999 employees) and jumbo employers (5,000+ employees) in the fall of 2013. They also conducted 25 interviews with employers (13), employee benefits consultants (5), subject matter experts (4) and health plans (3) in the winter of 2013-2014.

Newsletter Volume

E.V.I.dently January 2016

MessageThe Importance of Evidence, Value, Access and Innovation in 2016In his annual health care outlook, NPC President Dan Leonard explains why...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Blog Post

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and...
Blog Post

The Shift to Value-Based Care: Balancing Quality Improvement with Patient Access

Over the last few years, there has been a significant shift throughout our health care system to move to a delivery and payment model known as value-...
Press Release

Pharmaceuticals Play Key Role in Achieving ACO Quality, Cost Goals

WASHINGTON, DC, July 18, 2012–As health care providers set up accountable care organizations (ACOs) and other value-based care programs,...
Press Release

Avalere Explores Impact of Comparative Effectiveness Research on Healthcare Innovation

Washington, DC (November 17, 2009) – A new Avalere Health report presents an analytic framework for evaluating the impact of comparative...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
Commentary and Testimony Page

A Look at Value-Based Insurance Design

This month, NPC released a new report, “Value-Based Insurance Design Landscape Digest,” focusing on an important approach being used by leading edge...
Commentary and Testimony Page

NPC Submits Testimony on Draft CER Definition, Criteria and Framework

On behalf of the National Pharmaceutical Council (NPC), thank you for the opportunity to comment on the draft comparative effectiveness research (CER...
YouTube Videos

Accountable Care Measures for High-Cost Specialty Care and Innovative Treatment

Tom Valuck, MD, MHSA, JD, partner, Discern Health, is a co-author of the white paper "Accountable Care Measures for High-Cost Specialty Care and...
YouTube Videos

Patients, Research and Access to Health Care

Myrl Weinberg, FASAE, CAE, president of the National Health Council, says that it's important to for individuals, especially those with chronic...
YouTube Videos

Value-Based Insurance Design

National Pharmaceutical Council President Dan Leonard discusses a new report on Value-Based Insurance Design (VBID) with Dr. A. Mark Fendrick, Co-...
Blog Post

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and...
Blog Post

The Shift to Value-Based Care: Balancing Quality Improvement with Patient Access

Over the last few years, there has been a significant shift throughout our health care system to move to a delivery and payment model known as value-...
Blog Post

Consumer-Directed Health Plans & Employees' Health and Productivity

More employers are offering consumer-directed health plans (CDHPs), which are high-deductible plans offered in combination with an account that...
Blog Post

#TBT: Restrictive Formularies & Potential Pitfalls

As part of our Throwback Thursday blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research,...

Designing Successful Bundled Payment Initiatives

The National Pharmaceutical Council led a study that identified three principles intended to...

Developing Evidence that is Fit for Purpose: A Framework for Payer and Research Dialogue

A study published in the September 2015 issue of The American Journal of Managed Care introduces a...
  •  
  • 1 of 8
  • >